News

Deal Announcements

MAP Pharmaceuticals Raises $60 Million In IPO

Tuesday, October 9, 2007 5:00:00 AM PDT | VentureDeal Staff
MOUNTAIN VIEW, CA -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) publicly traded it shares for the first time, raising $60 million in gross proceeds from its IPO.

MAP is developing its proprietary Tempo Inhaler platform, a pressurized metered-dose inhaler (pMDI) that's designed to help deliver respiratory and systemic drug therapies via the pulmonary tract.

The company's investors included the D.E. Shaw Group, Perseus, LLC, Pequot Ventures, Skyline Ventures and Bay City Capital.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1